A CK5/6-positive result on a pathology report means that cells in your tissue sample are producing cytokeratin 5 and/or cytokeratin 6, structural proteins that normally line certain types of epithelial tissue such as the skin, esophagus, and the outer layers of organs like the lungs and bladder. Pathologists detect CK5/6 using a staining technique applied to thin slices of tissue, and the result helps them narrow down what kind of cells they are looking at. On its own, a CK5/6-positive finding is not a diagnosis of any specific disease, but it plays a surprisingly important role in distinguishing one type of cancer from another, sorting benign from precancerous breast lesions, and guiding treatment decisions in several organ systems.
What CK5/6 Actually Is
Cytokeratins are a family of about 20 different proteins that act as an internal scaffold for epithelial cells. Different tissues express different combinations of cytokeratins, which gives pathologists a kind of fingerprint for identifying where a cell came from and what type it is. CK5 and CK6 are found in basal and squamous-type epithelial cells, the cells that sit along the bottom layer or form the flat, tile-like surfaces of skin, the lining of the mouth, the cervix, the bronchial airways, and the bladder.
Because CK5 and CK6 are so closely associated with these particular cell types, they are powerful diagnostic clues. When a pathologist stains a tissue sample and finds CK5/6 positivity, the immediate implication is that the cells likely have a basal or squamous character. That single piece of information can rule out entire categories of disease or redirect the diagnostic workup toward a specific subtype of cancer.
One nuance worth knowing: CK5 and CK6 are actually separate proteins encoded by separate genes, and recent research has shown they do not always appear together. A large tissue study found that CK5 and CK6 expression patterns can diverge considerably between normal and cancerous tissues, meaning a tumor could be CK5-positive but CK6-negative or vice versa.1PubMed Central. Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications In everyday clinical practice, though, most labs still use a single antibody cocktail that detects both proteins together, and most pathology reports will simply say “CK5/6 positive” or “CK5/6 negative.”
How CK5/6 Helps Classify Lung Tumors
One of the most common reasons CK5/6 appears on a pathology report is lung cancer subtyping. If you have been diagnosed with non-small cell lung cancer, your oncologist needs to know whether the tumor is a squamous cell carcinoma or an adenocarcinoma, because the two subtypes respond to very different treatments. Some chemotherapy drugs work well against adenocarcinoma but are ineffective or even harmful for squamous cell carcinoma, and certain targeted therapies only apply to one subtype.
CK5/6 is one of the most reliable markers for making this distinction. Squamous cell carcinomas of the lung are strongly CK5/6-positive in the vast majority of cases, while adenocarcinomas are usually negative. In one large study of whole-tissue sections, squamous cell carcinomas displayed diffuse, strong CK5/6 staining, though the staining could be weaker or even absent in poorly differentiated tumors. Adenocarcinoma, by contrast, showed CK5/6 positivity in only about 18% of cases, and diffuse staining was rare at around 3%.2Modern Pathology. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens Another study found CK5/6 to have 100% specificity for distinguishing the two types, meaning that when it was positive, the tumor was reliably squamous.3PubMed. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung
Pathologists rarely rely on CK5/6 alone for this call. They typically use a small panel of stains, commonly including p63 and TTF-1, alongside CK5/6. A tumor that is CK5/6-positive, p63-positive, and TTF-1-negative is almost certainly squamous. One that is CK5/6-negative and TTF-1-positive points strongly toward adenocarcinoma. The panel approach guards against the occasional poorly differentiated squamous tumor that loses CK5/6 expression.
Separating Mesothelioma From Adenocarcinoma
Another major use of CK5/6 staining involves mesothelioma, a cancer of the lining of the lungs or abdomen. Mesothelioma and lung adenocarcinoma can look remarkably similar under the microscope, especially in biopsy or fluid samples, but the two diseases have very different treatment pathways and prognoses. CK5/6 is one of the key markers pathologists use to tell them apart.
Mesotheliomas are almost always CK5/6-positive. In one study, all 40 mesothelioma cases tested positive for CK5/6, while none of the 30 pulmonary adenocarcinomas showed any staining at all.4PubMed. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma A broader study of 509 cases confirmed that CK5/6 reactivity is seen in the vast majority of malignant mesotheliomas but only rarely in pulmonary adenocarcinomas.5Modern Pathology. Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases
When the sample in question is a fluid rather than a tissue biopsy, the picture gets somewhat muddier. In pleural effusion samples, one study found CK5/6 positivity in about 64% of mesotheliomas and 31% of reactive (non-cancerous) effusions, while all adenocarcinomas were negative.6PubMed. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology The lower sensitivity in fluid samples is one reason pathologists use CK5/6 alongside other markers like calretinin and D2-40 rather than depending on any single stain.
CK5/6 in Breast Cancer
If CK5/6 appears on a breast cancer pathology report, the context is usually different from lung or pleural disease. Here, the marker helps identify a particularly aggressive subtype called basal-like breast cancer, which overlaps heavily with triple-negative breast cancer (tumors that lack estrogen receptor, progesterone receptor, and HER2).
The basal-like subtype is identified in routine practice using a panel of four stains: estrogen receptor, HER2, CK5/6, and epidermal growth factor receptor (EGFR).7PubMed Central. Immunohistochemical characteristics of basal-like breast cancer A breast tumor that is ER-negative and HER2-negative but CK5/6-positive and/or EGFR-positive fits the basal-like profile. In a cross-sectional study of triple-negative breast cancers, roughly three-quarters tested positive for CK5/6.8NATIONAL JOURNAL OF LABORATORY MEDICINE. Clinicopathological Spectrum and Expression of Basal Markers CK5/6 and EGFR in Triple-Negative Breast Cancer: A Cross-sectional Study Other research in a Malaysian cohort confirmed the strong association between triple-negative status and CK5/6 expression.9PubMed Central. Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women
Why does the basal-like label matter? Because these tumors tend to be higher grade, grow faster, and cannot be treated with hormone therapy or HER2-targeted drugs. Identifying them correctly influences which chemotherapy regimens are recommended and may qualify patients for newer treatments like PARP inhibitors or immunotherapy.
Benign Versus Precancerous Breast Lesions
CK5/6 also plays a very different role in breast pathology: helping distinguish ordinary benign cell growth from early precancerous changes. When a breast biopsy shows an overgrowth of duct-lining cells, the pathologist must decide whether it is ordinary ductal hyperplasia (benign and common) or atypical ductal hyperplasia, which carries a higher risk of developing into cancer and sometimes requires further surgery.
This is where CK5/6 staining becomes especially useful. Ordinary ductal hyperplasia tends to show strong, diffuse CK5/6 positivity because the proliferating cells retain their normal basal characteristics. In contrast, atypical ductal hyperplasia and low-grade ductal carcinoma in situ show absent or only focal CK5/6 staining in the overwhelming majority of cases.10PubMed. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ So in this context, CK5/6 positivity is actually reassuring: it suggests a benign process rather than a worrisome one.
This can be confusing if you are reading your own report, because CK5/6-positive in a breast biopsy might mean very different things depending on whether the pathologist was evaluating a mass suspected to be cancer or a tiny area of cell overgrowth found on a screening biopsy. The surrounding context in the report, including other stain results and the pathologist’s interpretation, is what gives the finding its meaning.
Bladder Cancer Subtyping
Bladder cancer has undergone a molecular reclassification in recent years, and CK5/6 is central to it. Researchers have identified that muscle-invasive bladder cancers fall into subtypes that mirror the basal and luminal categories first described in breast cancer. Basal bladder tumors tend to express CK5/6 strongly and often show squamous features under the microscope, while luminal tumors express CK20 and other luminal markers instead.11Cancer Cell. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
This subtyping matters for prognosis and treatment planning. A simplified classification using GATA3, CK5/6, and p16 can divide bladder tumors into broad luminal and basal categories, with CK5/6 expression identifying the basal subtype.12Biomolecules and Biomedicine. Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16 Even in non-muscle-invasive disease, CK5/6 expression has prognostic value: tumors that simultaneously express both basal and luminal markers (a combined phenotype) are more likely to progress and metastasize than purely luminal tumors.13PubMed Central. Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma
Other Places CK5/6 Shows Up
Beyond lungs, breast, pleura, and bladder, CK5/6 staining appears on pathology reports from several other organs. In cervical cancer, CK5/6 helps distinguish squamous cell carcinoma from adenocarcinoma, with sensitivity for squamous differentiation reaching about 94% in one study.14PubMed Central. A combination of cytokeratin 5/6, p63, p40 and MUC5AC are useful for distinguishing squamous cell carcinoma from adenocarcinoma of the cervix In skin pathology, CK5/6 is diffusely positive in basal cell carcinoma, which helps pathologists separate it from Merkel cell carcinoma, a rarer and more aggressive skin cancer.15PubMed. Basal cell carcinoma: CD56 and cytokeratin 5/6 staining patterns in the differential diagnosis with Merkel cell carcinoma
When a patient presents with a metastatic tumor of unknown origin, meaning cancer has spread but doctors cannot immediately tell where it started, CK5/6 can help narrow the search. A CK5/6-positive metastatic carcinoma suggests the primary tumor arose from a squamous or basal-type epithelium, pointing the workup toward the lungs, head and neck, esophagus, cervix, or skin rather than the colon, pancreas, or prostate.
How Pathologists Score the Staining
If your report mentions CK5/6 intensity or percentage, the pathologist is grading how much staining is present and how strong it is. Scoring systems vary between labs, but a common approach grades intensity on a 0-to-3 scale: 0 means no staining, 1+ is weak, 2+ is moderate, and 3+ is strong. The percentage of tumor cells that stain positive is also recorded, and the combination of the two produces an overall staining index.16European Journal of Cardiovascular Medicine. Role of CK5/6 in Breast Tumors: IHC Insights into Benign and Malignant Differentiation
The distinction between focal and diffuse staining matters clinically. “Diffuse” CK5/6 positivity, where most of the tumor lights up, strongly supports a squamous or basal identity. “Focal” positivity, where only scattered patches stain, is more ambiguous and does not necessarily indicate a squamous lineage. This is why the lung cancer studies described earlier found that while adenocarcinomas occasionally showed some CK5/6 staining, diffuse staining was exceedingly rare in that subtype.
Does CK5/6 Status Affect Treatment Decisions?
In most settings, CK5/6 is primarily a diagnostic marker rather than a direct driver of treatment selection. Its main job is to help categorize the tumor so that the correct treatment pathway follows from the diagnosis. If CK5/6 staining helps confirm that a lung tumor is squamous, for instance, the treatment implications flow from the squamous diagnosis itself, not from the CK5/6 result per se.
In triple-negative breast cancer, however, CK5/6 status has attracted research interest as a potential predictor of chemotherapy response. One study found that tumors expressing CK5/6 and/or EGFR showed a higher rate of tumor shrinkage with neoadjuvant chemotherapy compared to tumors lacking both markers in estrogen-receptor-negative patients.17Advances in Modern Medicine. Is It Possible to Optimize Neoadjuvant Chemotherapy Response by EGFR and CK5/6 Expression Status in Breast Cancer Patients? Separately, research tracking CK5/6 expression before and after chemotherapy found that while changes in CK5/6 status did not significantly alter the overall chemotherapy response, a shift from positive to negative expression tended to be associated with better outcomes.18PubMed Central. Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer These findings are still in the realm of research rather than standard clinical guidelines, but they point toward a future where CK5/6 could play a more active role in selecting or monitoring therapy.
What CK5/6 Positive Does Not Mean
The most common misunderstanding among patients who read their own pathology reports is treating CK5/6 positivity as though it is a diagnosis. It is not. CK5/6 is one data point in a larger puzzle. Normal, healthy tissues express CK5/6, including skin, the lining of the airways, and the myoepithelial cells that surround breast ducts. A CK5/6-positive result does not mean cancer is present, and a CK5/6-negative result does not mean cancer has been ruled out.
Similarly, CK5/6 positivity does not indicate a worse prognosis in every context. In breast biopsies, as described earlier, diffuse CK5/6 staining in a proliferative duct lesion is actually a good sign, pointing toward benign hyperplasia rather than atypical growth. In breast cancer, CK5/6 positivity flags the basal-like subtype, which does carry a more aggressive profile, but the outcome depends on many other factors including tumor grade, stage, and response to chemotherapy. In lung cancer, CK5/6 tells your team which subtype they are dealing with so they can choose the right drugs; it is not itself a marker of better or worse survival.
If CK5/6 appears on your pathology report and you are uncertain what it means for your specific situation, the most productive step is to ask your treating physician how the result fits into your overall diagnosis. The pathologist uses CK5/6 as a tool within a panel of other markers and histologic features, and the final interpretation depends on that full context.
CK5/6 Beyond Cancer
Although most of the clinical attention around CK5/6 concerns tumor classification, the proteins themselves play important roles in normal cell biology. Keratin 5, one half of the CK5/6 pair, is a structural protein whose gene, KRT5, is well known in dermatology. Mutations in KRT5 or its partner KRT14 are the cause of epidermolysis bullosa simplex, a group of inherited skin blistering conditions. In about three-quarters of patients with this disease, a mutation in one of these two genes can be identified.19PubMed Central. Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients The mutations weaken the internal scaffold of skin cells, causing them to rupture with minimal friction. This connection illustrates that CK5 is not inherently a “cancer protein”; it is a normal structural component whose presence or absence in a tissue sample simply tells the pathologist something about the identity of the cells.
Researchers have also explored CK5/6 as a marker for specific rare tumor subtypes beyond the major cancers discussed above. In cervical pathology, for example, a recently described entity called invasive stratified mucin-producing carcinoma shows a distinct CK5/6 pattern that helps separate it from both standard endocervical adenocarcinoma and squamous cell carcinoma. In that context, the combination of CK5/6, PAX8, and p63 has been proposed as a diagnostic triple panel.20PubMed Central. Immunohistochemical and genetic characteristics of HPV-associated endocervical carcinoma with an invasive stratified mucin-producing carcinoma (ISMC) component As pathology continues to refine tumor classification, CK5/6 will likely keep appearing in new and more specialized diagnostic panels.